Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors.

A single-cycle infection assay with recombinant viral vectors was developed to study human T cell leukemia virus type I (HTLV-I) replication and its inhibition by antiviral agents. The susceptibility of HTLV-I to 6 nucleoside reverse-transcriptase inhibitors was examined. HTLV-I replication was inhibited by tenofovir, abacavir, lamivudine, zalcitabine, stavudine, and zidovudine.

[1]  F. Bolgert,et al.  The effect of zidovudine on chronic myelopathy associated with HTLV-1 , 1991, Journal of Neurology.

[2]  G. Forte,et al.  Effect of Lamivudine on Transmission of Human T-Cell Lymphotropic Virus Type 1 to Adult Peripheral Blood Mononuclear Cells In Vitro , 2002, Antimicrobial Agents and Chemotherapy.

[3]  S. Grelli,et al.  Efficacy of 3'-azido 3'deoxythymidine (AZT) in preventing HTLV-1 transmission to human cord blood mononuclear cells. , 2001, Virus research.

[4]  D. Derse,et al.  Examining Human T-Lymphotropic Virus Type 1 Infection and Replication by Cell-Free Infection with Recombinant Virus Vectors , 2001, Journal of Virology.

[5]  W. Heneine,et al.  Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine. , 2001, The Journal of infectious diseases.

[6]  J. Cavenagh,et al.  Interferon α and zidovudine therapy in adult T‐cell leukaemia lymphoma: response and outcome in 15 patients , 2001, British journal of haematology.

[7]  C. L. Hill,et al.  Differential Susceptibility of Retroviruses to Nucleoside Analogues , 2001, Antiviral chemistry & chemotherapy.

[8]  C. Bangham.  HTLV-1 infections , 2000, Journal of clinical pathology.

[9]  M. Nowak,et al.  Effect of Lamivudine on Human T-Cell Leukemia Virus Type 1 (HTLV-1) DNA Copy Number, T-Cell Phenotype, and Anti-Tax Cytotoxic T-Cell Frequency in Patients with HTLV-1-Associated Myelopathy , 1999, Journal of Virology.

[10]  A. Manns,et al.  Human T-lymphotropic virus type I infection , 1999, The Lancet.

[11]  R. V. Srinivas,et al.  Antiviral Activities of 9-R-2-Phosphonomethoxypropyl Adenine (PMPA) and Bis(isopropyloxymethylcarbonyl)PMPA against Various Drug-Resistant Human Immunodeficiency Virus Strains , 1998, Antimicrobial Agents and Chemotherapy.

[12]  Jing Zhang,et al.  AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro. , 1997, The Journal of general virology.

[13]  F. Ruscetti,et al.  Examining the molecular genetics of HTLV-I with an infectious molecular clone of the virus and permissive cell culture systems. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[14]  M. Kaplan,et al.  Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. , 1995, The New England journal of medicine.

[15]  P. Skinhøj.  [HTLV infections]. , 1994, Ugeskrift for laeger.

[16]  W. Sheremata,et al.  High‐dose zidovudine induction in HTLV‐I‐associated myelopathy , 1993, Neurology.

[17]  S D Kemp,et al.  Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[18]  E. De Clercq,et al.  The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species. , 1988, Biochemical pharmacology.

[19]  M. Reitz,et al.  Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I. , 1987, The Journal of clinical investigation.